Health Canada has approved Novartis‘ Bexsero (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) for use in individuals from two months through 17 years of age. Bexsero is the first broad coverage vaccine to help protect against meningococcal serogroup B (MenB) disease, including infants, toddlers and adolescents who are at the greatest risk of infection.   Meningococcal disease is caused by Neisseria meningitidis. Five main groups of meningococcal bacteria (A, B, C, W and...